Clifford Chance Advised CVC Capital Partners on Acquisition of Sogo Medical Group from Polaris Capital
International law firm Clifford Chance has advised leading global private equity firm CVC Capital Partners on a 100 percent
Clifford Chance Advised CVC Capital Partners on Acquisition of Sogo Medical Group from Polaris Capital The Luxembourg-based private equity and investment advisory firm has seven complementary strategies International law firm Clifford Chance has advised leading global private equity firm CVC Capital Partners on a 100 percent acquisition of Japanese pharmacy operator Sogo Medical...
Clifford Chance Advised CVC Capital Partners on Acquisition of Sogo Medical Group from Polaris Capital
The Luxembourg-based private equity and investment advisory firm has seven complementary strategies
International law firm Clifford Chance has advised leading global private equity firm CVC Capital Partners on a 100 percent acquisition of Japanese pharmacy operator Sogo Medical Group Company Limited from Polaris Capital Group and other shareholders.
Sogo, Japan's fifth-largest pure pharmacy chain, provides a comprehensive range of services related to the management of medical practices. It has an extensive network of 740 pharmacies nationwide.
Michihiro Nishi, the Tokyo partner at Clifford Chance stated, "We are honored to advise long-standing client CVC on this landmark transaction, one of the largest private equity-backed M&A deals in Japan's healthcare sector last year. With the country's aging population, the depreciation of the Japanese yen and an enhanced environment for corporate governance, Japan's healthcare sector is increasingly an attractive target for private capital investors seeking to unlock long-term value. We wish CVC and Sogo Medical every success in their next chapter of growth."
Clifford Chance has extensive experience advising on healthcare transactions in Asia Pacific. It has advised CVC on its buyout of Xi'an Yikang Pharmacy in China, Seatown on its majority acquisition of Foundation Healthcare in Singapore and Prenetics on its majority acquisition of ACT Genomics.
The law firm advised on the M&A and antitrust aspects of the transaction. The team was led by Michihiro Nishi. It included counsel Masafumi Shikakura and senior associates Shunsuke Nagae and Yuki Hoshinaga.